Harbour Investment Management LLC Has $5.13 Million Position in iShares Biotechnology ETF (NASDAQ:IBB)

Harbour Investment Management LLC increased its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 2.9% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 39,695 shares of the financial services provider’s stock after acquiring an additional 1,110 shares during the period. iShares Biotechnology ETF comprises about 2.8% of Harbour Investment Management LLC’s portfolio, making the stock its 6th biggest position. Harbour Investment Management LLC owned about 0.07% of iShares Biotechnology ETF worth $5,127,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of IBB. Moneta Group Investment Advisors LLC grew its stake in shares of iShares Biotechnology ETF by 131,598.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 4,469,845 shares of the financial services provider’s stock worth $586,846,000 after purchasing an additional 4,466,451 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of iShares Biotechnology ETF by 49.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,568,159 shares of the financial services provider’s stock valued at $204,332,000 after buying an additional 521,820 shares during the period. Bank of Nova Scotia raised its position in shares of iShares Biotechnology ETF by 13,605.4% during the fourth quarter. Bank of Nova Scotia now owns 402,940 shares of the financial services provider’s stock worth $52,902,000 after acquiring an additional 400,000 shares during the last quarter. Johns Hopkins University lifted its stake in shares of iShares Biotechnology ETF by 280.3% in the fourth quarter. Johns Hopkins University now owns 475,389 shares of the financial services provider’s stock worth $62,414,000 after acquiring an additional 350,389 shares during the period. Finally, Citigroup Inc. boosted its holdings in iShares Biotechnology ETF by 18.1% in the first quarter. Citigroup Inc. now owns 2,000,532 shares of the financial services provider’s stock valued at $258,389,000 after acquiring an additional 306,853 shares during the last quarter. Institutional investors and hedge funds own 69.61% of the company’s stock.

iShares Biotechnology ETF Stock Down 1.1 %

iShares Biotechnology ETF stock traded down $1.45 during mid-day trading on Tuesday, hitting $128.56. 925,991 shares of the stock were exchanged, compared to its average volume of 1,526,718. The firm’s fifty day simple moving average is $127.87 and its two-hundred day simple moving average is $129.54. iShares Biotechnology ETF has a 12 month low of $113.37 and a 12 month high of $138.74.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.